Gadolinium Contrast Agents for CNS Imaging: Current Concepts and Clinical Evidence

References

1. 1.↵
   Dotarem product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf. Accessed May 10, 2013.
2. 2.↵
   Gadavist product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf. Accessed May 10, 2013.
3. 3.↵
   Magnevist product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019596s051lbl.pdf. Accessed May 10, 2013.
4. 4.↵
   MultiHance product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021357s009lbl.pdf. Accessed May 10, 2013.
5. 5.↵
   Omniscan product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020123s037lbl.pdf. Accessed May 10, 2013.
6. 6.↵
   OptiMARK product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020937s016lbl.pdf. Accessed 10 May 10, 2013.
7. 7.↵
   ProHance product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020131s024lbl.pdf. Accessed May 10, 2013.
8. 8.↵
   Ablavar product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021711s003lbl.pdf. Accessed May 10, 2013.
9. 9.↵
   Eovist product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022090s004lbl.pdf. Accessed May 10, 2013.
10. 10.↵
    2. Bellin MF,
    3. Van Der Molen AJ

    . Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008;66:160–67

    CrossRefPubMed
11. 11.↵
    2. Rohrer M,
    3. Bauer H,
    4. Mintorovitch J, et al

    . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Cavagna FM,
    3. Maggioni F,
    4. Castelli PM, et al

    . Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780–96

    CrossRefPubMed
13. 13.↵
    2. Giesel FL,
    3. von Tengg-Kobligk H,
    4. Wilkinson ID, et al

    . Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 2006;41:222–28

    CrossRefPubMed
14. 14.↵
    2. Pintaske J,
    3. Martirosian P,
    4. Graf H, et al

    . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadavist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21, Erratum in Invest Radiol 2006;41:859

    CrossRefPubMed
15. 15.↵
    2. Laurent S,
    3. Elst LV,
    4. Muller RN

    . Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1:128–37

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Yuh WT,
    3. Fisher DJ,
    4. Engelken JD, et al

    . MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485–91

    CrossRefPubMed
17. 17.↵
    2. Myhr G,
    3. Rinck PA,
    4. Børseth A

    . Gadodiamide injection and gadopentetate dimeglumine: a double-blind study in MR imaging of the CNS. Acta Radiol 1992;33:405–09

    Abstract/FREE Full Text
18. 18.↵
    2. Balériaux D,
    3. Matos C,
    4. De Greef D

    . Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 1993;35:490–94

    CrossRefPubMed
19. 19.↵
    2. Valk J,
    3. Algra PR,
    4. Hazenberg CJ, et al

    . A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 1993;35:173–77

    CrossRefPubMed
20. 20.↵
    2. Brugières P,
    3. Gaston A,
    4. Degryse HR, et al

    . Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 1994;36:27–30

    CrossRefPubMed
21. 21.↵
    2. Akeson P,
    3. Jonsson E,
    4. Haugen I, et al

    . Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995;37:229–33

    CrossRefPubMed
22. 22.↵
    2. Oudkerk M,
    3. Sijens PE,
    4. van Beek EJ, et al

    . Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75–78

    CrossRefPubMed
23. 23.↵
    2. Grossman RI,
    3. Rubin DI,
    4. Hunter G, et al

    . Magnetic resonance imaging in patients with central nervous system pathology: q comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000;35:412–19

    CrossRefPubMed
24. 24.↵
    2. Runge VM,
    3. Armstrong MR,
    4. Barr RG, et al

    . A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 2001;36:65–71

    CrossRefPubMed
25. 25.↵
    2. Runge VM,
    3. Parker JR,
    4. Donovan M

    . Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 2002;37:269–80

    CrossRefPubMed
26. 26.↵
    2. Greco A,
    3. Parker JR,
    4. Ratcliffe CG, et al

    . Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001;45:457–63

    CrossRefPubMed
27. 27.↵
    2. Anzalone N,
    3. Gerevini S,
    4. Scotti R, et al

    . Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 2009;50:933–40

    Abstract/FREE Full Text
28. 28.↵
    2. Kim ES,
    3. Chang JH,
    4. Choi HS, et al

    . Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol 2010;31:1055–58

    Abstract/FREE Full Text
29. 29.↵
    2. Katakami N,
    3. Inaba Y,
    4. Sugata S, et al

    . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0M compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 2011;46:411–18

    CrossRefPubMed
30. 30.↵
    2. Koenig M,
    3. Schulte-Altedorneburg G,
    4. Piontek M, et al

    . Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol 2013;23:3287–95

    CrossRefPubMed
31. 31.↵
    Center for Drug Evaluation and Research. FDA Advisory Committee Briefing Document. New Drug Application 201–277. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm255169.pdf. Accessed February 6, 2014.
32. 32.↵
    2. Anzalone N,
    3. Scarabino T,
    4. Venturi C, et al

    . Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139–45

    CrossRefPubMed
33. 33.↵
    2. Colosimo C,
    3. Ruscalleda J,
    4. Korves M, et al

    . Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol 2001;36:72–81

    CrossRefPubMed
34. 34.↵
    2. Knopp MV,
    3. Runge VM,
    4. Essig M, et al

    . Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55–64

    CrossRefPubMed
35. 35.↵
    2. Colosimo C,
    3. Knopp MV,
    4. Barreau X, et al

    . A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 2004;46:655–65

    PubMed
36. 36.↵
    2. Essig M,
    3. Tartaro A,
    4. Tartaglione T, et al

    . Enhancing lesions of the brain: intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Academic Radiology 2006;13:744–51

    CrossRefPubMed
37. 37.↵
    2. Maravilla KR,
    3. Maldjian JA,
    4. Schmalfuss IM, et al

    . Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389–400

    CrossRefPubMed
38. 38.↵
    2. Kuhn MJ,
    3. Picozzi P,
    4. Maldjian JA, et al

    . Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557–66

    CrossRefPubMed
39. 39.↵
    2. Rowley HA,
    3. Scialfa G,
    4. Gao PY, et al

    . Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684–91

    Abstract/FREE Full Text
40. 40.↵
    2. Rumboldt Z,
    3. Rowley HA,
    4. Steinberg F, et al

    . Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760–67

    CrossRefPubMed
41. 41.↵
    2. Seidl Z,
    3. Vymazal J,
    4. Mechl M, et al

    . Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012;33:1050–58

    Abstract/FREE Full Text
42. 42.↵
    2. Griffiths PD,
    3. Wilkinson ID,
    4. Wels T, et al

    . Brain MR perfusion imaging in humans. Acta Radiol 2001;42:555–59

    FREE Full Text
43. 43.↵
    2. Griffiths PD,
    3. Pandya H,
    4. Wilkinson ID, et al

    . Sequential dynamic gadolinium magnetic resonance perfusion-weighted imaging: effects on transit time and cerebral blood volume measurements. Acta Radiol 2006;47:1079–84

    FREE Full Text
44. 44.↵
    2. Giesel FL,
    3. Mehndiratta A,
    4. Risse F, et al

    . Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla. Acta Radiol 2009;50:521–30

    Abstract/FREE Full Text
45. 45.↵
    2. Essig M,
    3. Lodemann KP,
    4. Le-Huu M, et al

    . Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 2006;41:256–63

    CrossRefPubMed
46. 46.↵
    2. Thilmann O,
    3. Larsson EM,
    4. Björkman-Burtscher IM, et al

    . Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 2005;22:597–604

    CrossRefPubMed
47. 47.↵
    2. Wirestam R,
    3. Thilmann O,
    4. Knutsson L, et al

    . Comparison of quantitative dynamic susceptibility-contrast MRI perfusion estimates obtained using different contrast-agent administration schemes at 3T. Eur J Radiol 2010;75:e86–91

    CrossRefPubMed
48. 48.↵
    2. Beranek-Chiu J,
    3. Froehlich JM,
    4. Wentz KU, et al

    . Improved vessel delineation in keyhole time-resolved contrast-enhanced MR angiography using a gadolinium doped flush. J Magn Reson Imaging 2009;29:1147–53

    CrossRefPubMed
49. 49.↵
    2. Pediconi F,
    3. Fraioli F,
    4. Catalano C, et al

    . Gadobenate dimeglumine (Gd-BOPTA) vs gadopentetate dimeglumine (Gd-DTPA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. Radiol Med 2003;106:87–93

    PubMed
50. 50.↵
    2. Li Y,
    3. Li X,
    4. Li D, et al

    . Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic Value Study). AJNR Am J Neuroradiol 2013;34:847–54

    Abstract/FREE Full Text
51. 51.↵
    2. Bültmann E,
    3. Erb G,
    4. Kirchin MA, et al

    . Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol 2008;43:695–702

    CrossRefPubMed
52. 52.↵
    2. Kramer JH,
    3. Arnoldi E,
    4. François CJ, et al

    . Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose. Invest Radiol 2013;48:121–8

    CrossRefPubMed
53. 53.↵
    2. Pirovano G,
    3. Munley J,
    4. Schultz C, et al

    . Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. Insights Imaging 2012;3(suppl 1):S293
54. 54.↵
    2. Idée JM,
    3. Port M,
    4. Robic C, et al

    . Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009;30:1249–58

    CrossRefPubMedWeb of Science
55. 55.↵
    2. Bennett CL,
    3. Qureshi ZP,
    4. Sartor AO, et al

    . Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82–88

    Abstract/FREE Full Text
56. 56.↵
    2. Abujudeh HH,
    3. Kosaraju VK,
    4. Kaewlai R

    . Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 21,659 injections. AJR Am J Roentgentol 2010;194:430–34

    CrossRefPubMedWeb of Science
57. 57.↵
    American College of Radiology. Manual on Contrast Media. Version 9. 2013. http://www.acr.org. Accessed January 4, 2013.
58. 58.↵
    2. Bruder O,
    3. Schneider S,
    4. Nothnagel D, et al

    . Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry. JACC Cardiovasc Imaging 2011;4:1171–76

    CrossRefPubMedWeb of Science
59. 59.↵
    2. Cochran ST,
    3. Bomyea K,
    4. Sayre JW

    . Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001;176:1385–88

    CrossRefPubMedWeb of Science
60. 60.↵
    2. Forsting M,
    3. Palkowitsch P

    . Prevalence of acute adverse reactions to gadobutrol: a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol 2010;74:e186–92

    CrossRefPubMed
61. 61.↵
    2. Murphy KP,
    3. Szopinski KT,
    4. Cohal RH, et al

    . Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999;6:656–64

    CrossRefPubMedWeb of Science
62. 62.↵
    2. Li A,
    3. Wong CS,
    4. Wong MK, et al

    . Acute adverse reactions to magnetic resonance contrast media: gadolinium chelates. Br J Radiol 2006;79:368–71

    Abstract/FREE Full Text
63. 63.↵
    2. Dillman JR,
    3. Ellis JH,
    4. Cohan RH, et al

    . Frequency and severity of acute allergic-like reactions to gadolinium-containing I.V. contrast media in children and adults. AJR Am J Roentgenol 2007;189:1533–38

    CrossRefPubMedWeb of Science
64. 64.↵
    2. Hunt CH,
    3. Hartman RP,
    4. Hesley GK

    . Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009;193:1124–27

    CrossRefPubMedWeb of Science
65. 65.↵
    2. Prince MR,
    3. Zhang H,
    4. Zou Z, et al

    . Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011;196:W138–43

    CrossRefPubMedWeb of Science
66. 66.↵
    2. Jung JW,
    3. Kang HR,
    4. Kim MH, et al

    . Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 2012;264:414–22

    CrossRefPubMed
67. 67.↵
    2. Vervloet D,
    3. Durham S

    . Adverse reactions to drugs. BMJ 1998;316:1511–14

    FREE Full Text
68. 68.↵
    2. Hasdenteufel F,
    3. Luyasu S,
    4. Renaudin JM, et al

    . Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment. J Allergy Clin Immunol 2008;121:527–28

    CrossRefPubMed
69. 69.↵
    2. Schiavino D,
    3. Murzilli F,
    4. Del Ninno M, et al

    . Demonstration of an IgE-mediated immunological pathogenesis of a severe reaction to gadopentetate dimeglumine. J Invest Allergol Clin Immunol 2003;13:140–42

    PubMed
70. 70.↵
    European Society on Urogenital Radiology (ESUR). ESUR Guidelines on Contrast Media. Version 8.1. http://www.esur.org/esur-guidelines/. Accessed January 4, 2013.
71. 71.↵
    United States of America ex rel. Lynch vs. Imagimed LLC, et al. (N.D. N.Y.); as reported on http://www.justice.gov/opa/pr/2013/August/13-civ-958.html. Accessed September 14, 2013.
72. 72.↵
    2. Runge V

    . Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000;12:205–13

    CrossRefPubMed
73. 73.↵
    2. Bleicher AG,
    3. Kanal E

    . Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191:W307–11

    CrossRefPubMedWeb of Science
74. 74.↵
    2. Shellock FG,
    3. Parker JR,
    4. Venetianer C, et al

    . Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol 2006;41:500–09

    CrossRefPubMed
75. 75.↵
    2. Shellock FG,
    3. Parker JR,
    4. Pirovano G, et al

    . Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006;24:1378–85, Erratum in J Magn Reson Imaging 2007;26:217

    CrossRefPubMed
76. 76.↵
    1. Rainsford KD,
    2. Velo GP

    2. Weber JC

    . Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drug. In: Rainsford KD, Velo GP, eds. Side Effects of Antiinflammatory/Analgesic Drugs Advances in Inflammation Research. Vol. 6. New York: Raven Press; 1984:1–7
77. 77.↵
    2. Lalli AF

    . Urographic contrast media reactions and anxiety. Radiology 1974;112:267–71

    CrossRefPubMed
78. 78.↵
    2. Semelka RC,
    3. Hernandes Mde A,
    4. Stallings CG, et al

    . Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation: pilot study. Magn Reson Imaging 2013;31:96–101

    CrossRefPubMed
79. 79.↵
    2. Davenport MS,
    3. Dillman JR,
    4. Cohan RH, et al

    . Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 2013;266:773–82

    CrossRefPubMed
80. 80.↵
    2. van Osch MJ,
    3. Vonken EJ,
    4. Wu O, et al

    . Model of the human vasculature for studying the influence of contrast injection speed on cerebral perfusion MRI. Magn Reson Med 2003;50:614–22

    CrossRefPubMed
81. 81.↵
    2. Prokop M,
    3. Schneider G,
    4. Vanzulli A, et al

    . Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2005;234:399–408

    CrossRefPubMed
82. 82.↵
    2. Gerretsen SC,
    3. le Maire TF,
    4. Miller S, et al

    . Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010;255:988–1000

    CrossRefPubMed
83. 83.↵
    2. Knopp MV,
    3. Giesel FL,
    4. von Tengg-Kobligk H, et al

    . Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging 2003;17:694–702

    CrossRefPubMed
84. 84.↵
    2. Stein PD,
    3. Chenevert TL,
    4. Fowler SE, et al

    . Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 2010;152:434–43, W142–43

    CrossRefPubMedWeb of Science
85. 85.↵
    2. Woodard PK,
    3. Chenevert TL,
    4. Sostman HD, et al

    . Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine. Int J Cardiovasc Imaging 2012;28:295–301

    CrossRefPubMed
86. 86.↵
    2. Wang J,
    3. Yan F,
    4. Liu J, et al

    . Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the peripheral VALUE study). J Magn Reson Imaging 2013;38:926–37

    CrossRefPubMed